Trial Profile
Phase III study of Metadoxine Extended Release in adolescents and adult patients with Fragile X Syndrome
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- Sponsors Alcobra; Arcturus Therapeutics
- 15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
- 19 Feb 2016 New trial record
- 17 Feb 2016 According to Alcobra media release, company plans to initiate this trial following the November 2015 meeting with the U.S. Food and Drug Administration (FDA).